Replimune Group, Inc. reported earnings results for the first quarter ended June 30, 2023. For the first quarter, the company reported net loss was USD 49.56 million compared to USD 42.25 million a year ago. Basic loss per share from continuing operations was USD 0.75 compared to USD 0.78 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.42 USD | +4.39% | -0.47% | -23.84% |
Apr. 08 | Replimune Group Provides Interim Results for Skin Cancer Therapy | MT |
Mar. 26 | Replimune Group, Inc. Announces Management Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.84% | 394M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- REPL Stock
- News Replimune Group, Inc.
- Replimune Group, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023